ResearcherUniversity of North Carolina at Chapel HillNo recent work listed
Ye S. Lee
Matched on ORCID iD 0000-0001-9026-6192; OpenAlex author ID A5006161831. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2021: 1 paper · 2022: none · 2023: 1 paper
Papers 2
- VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. Co-author DOI 10.18632/genesandcancer.231↗
- CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. First author DOI 10.1016/j.celrep.2021.110060↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kirsten L. Bryant · 2 shared papers, 2021–2023 · strength 0.27
- Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
- Adrienne D. Cox · 2 shared papers, 2021–2023 · strength 0.27
- Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
- Jennifer E. Klomp · 2 shared papers, 2021–2023 · strength 0.27
- Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
- Clint A. Stalnecker · 2 shared papers, 2021–2023 · strength 0.27
- Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
- Channing J. Der · 2 shared papers, 2021–2023 · strength 0.27
- Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
- Craig M. Goodwin · 2 shared papers, 2021–2023 · strength 0.27
- Paper VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target… DOI 10.18632/genesandcancer.231↗
- Paper CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. DOI 10.1016/j.celrep.2021.110060↗
- Cyrus Vaziri · 1 shared paper, 2023 · strength 0.18
- Jonathan M. DeLiberty · 1 shared paper, 2021 · strength 0.09
- Kristina Drizyte‐Miller · 1 shared paper, 2021 · strength 0.09
- Bjoern Papke · 1 shared paper, 2021 · strength 0.09
- Emanuel F. Petricoin · 1 shared paper, 2021 · strength 0.09
- J. Nathaniel Diehl · 1 shared paper, 2021 · strength 0.09
- Calvin Jay Kuo · 1 shared paper, 2021 · strength 0.09
- Mariaelena Pierobon · 1 shared paper, 2021 · strength 0.09
- Christopher M Counter · 1 shared paper, 2021 · strength 0.09
- Andrew M. Waters · 1 shared paper, 2021 · strength 0.09
- Meagan B. Ryan · 1 shared paper, 2021 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.